Identification of the metabolic protein ATP5MF as a potential therapeutic target of TNBC

Kaiyan Chen1,2, Yingchun Wu3, Linfeng Xu1

  • 1Department of General Surgery, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210011, Jiangsu, China.

PubMed
Abstract

Insights

This study identifies ATP5MF as a key metabolic protein driving triple-negative breast cancer (TNBC) growth in non-BRCA1/2 mutations. Silencing ATP5MF inhibits TNBC progression and offers a potential new therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Triple-negative breast cancer (TNBC) presents significant challenges due to its aggressive nature and limited treatment options for non-BRCA1/2 mutations.
  • There is a critical need for novel therapeutic strategies to improve outcomes for patients with non-BRCA1/2 mutation TNBC.

Purpose of the Study:

  • To identify novel therapeutic targets for non-BRCA1/2 mutation TNBC.
  • To investigate the role of ATP5MF in TNBC progression and its potential as a therapeutic target.

Main Methods:

  • Utilized high-dimensional weighted gene coexpression network analysis (hdWGCNA) on single-cell RNA sequencing data from TNBC.
  • Performed protein-protein interaction (PPI) and survival analyses to identify key genes.
  • Investigated the functional impact of ATP5MF silencing in TNBC cell lines and a xenograft mouse model.

Main Results:

  • Identified ATP5MF as a key gene associated with poor prognosis in non-BRCA1/2 mutation TNBC.
  • Demonstrated that ATP5MF silencing reduces TNBC cell proliferation, colony formation, and migration in vitro.
  • Showed that ATP5MF knockdown inhibits tumor growth in vivo and impairs mitochondrial function in TNBC cells.

Conclusions:

  • The metabolic protein ATP5MF is crucial for the survival and proliferation of non-BRCA1/2 mutation TNBC cells.
  • ATP5MF represents a promising novel diagnostic and therapeutic target for non-BRCA1/2 mutation TNBC.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
ATP Synthase: Mechanism01:48

ATP Synthase: Mechanism

In animals, the mitochondrial F1F0 ATP synthase is the key protein that synthesizes ATP molecules through a complex catalytic mechanism. While the nuclear genome encodes the majority of ATP synthase subunits, the mitochondrial genome encodes some of the enzyme's most critical components. The formation of this multi-subunit enzyme is a complex multi-step process regulated at the level of transcription, translation, and assembly. Defects in one or more of these steps can result in decreased...
14.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
12.1K